An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol. (2022)
Attributed to:
The generation and maintenance of genetic novelty in helminth populations
funded by
UKRI FLF
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.12688/gatesopenres.13615.1
PubMed Identifier: 36540062
Publication URI: http://europepmc.org/abstract/MED/36540062
Type: Journal Article/Review
Volume: 6
Parent Publication: Gates open research
ISSN: 2572-4754